Gemtuzumab for relapsed acute myeloid leukemia.
D000208:Acute Disease; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003365:Costs and Cost Analysis; D004155:Diphenhydramine / Q000627:therapeutic use; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use; D007262:Infusions, Intravenous / Q000191:economics; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008875:Middle Aged; D011292:Premedication
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D004155:Diphenhydramine; D000079982:Gemtuzumab